New Street Research - Indus Towers Limited (INDUSTOWER) Indus Towers (Neutral, pt INR 265, +18%) AMT sells Indian Towers - Implications for Indus Towers

Report

New Street Research

Chris Hoare

EUR 9453.00 For Business Accounts Only

Indus Towers (Neutral, pt INR 265, +18%) AMT sells Indian Towers - Implications for Indus Towers

American Tower ("AMT") has agreed to sell its Indian Towers business, ATC India, to an affiliate of Brookfield Asset Management, with the deal expected to close in 2H 2024. The transaction values the Indian business at US$ 2 bn which implies a 5.6x EV/EBITDA, 17% above Indus’ trading multiple, but in line with our target multiple.

05/01/2024 1 EN

Underlying

Indus Towers Limited

Bharti Infratel provides telecom tower infrastructure in India. Co. acquires, builds, owns, operates, and manages towers and related infrastructure for wireless telecommunications service providers. As of Mar 31 2014, Co. owned and operated 83,368 towers and 167,202 co-locations in 22 telecommunication circles.

See profile

INE121J01017 National Stock Exchange of India India

Provider

New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

Pan European Telecom Services and Cable
US Telecoms, Cable, Satellite and Towers
Global Emerging Market Telecoms
Japan Telecoms
Asian Internet
Pan European Healthcare
Global healthcare thematic research

We provide debt research on:

Pan European Telecom Services and Cable

See profile

Analysts

Chris Hoare

Other Reports on these Companies

New Street Research

Indus Towers (Reduce, INR 280 from INR 265, -26%) Implications for Indus of likely VIL nationalisation

In this note we address the implications for Indus of creeping nationalisation at VIL, as explained in a separate note out today. Spoiler alert: they aren’t good.

EUR 9453.00

October 14, 2024 October 14, 2024 1 EN

New Street Research

Indus Towers (Reduce, TP: INR265, -40%) Proposed share buyback. Our thoughts.

Shares of Indus Towers jumped 4% today after it announced that it will consider share repurchases in the upcoming Board meeting on 30 July. This will be its first share repurchase since 2016. We share our brief thoughts below.

EUR 9453.00

July 26, 2024 July 26, 2024 1 EN

New Street Research

Indian Mobile VIL Capital Increase – should you participate and what does it mean for Bharti, Jio and Indus? Indus to Reduce

Sometimes the markets behave in ways that appear irrational. VIL having sufficient market cap to launch an INR 200bn ($2.4bn) capital increase despite (in our view) being a failing business is one example. But what does it mean for Bharti, Jio and Indus?

EUR 9453.00

April 15, 2024 April 15, 2024 1 EN

TalkTalk H1 results: Guidance looks at risk

TalkTalk has reported its H1 results to August, albeit given the lack of an investor presentation, it is hard to decipher all the changes vs. their guidance at this stage, but we think the numbers are at the low end of any prior guidance. We are still also critically waiting for any disclosure on KPIs since February, but we think the risk is to the downside given Openreach disclosure.

EUR 9453.00

17h / 19m 17h / 19m 1 EN

Russell Waller

Russell Waller

Odido (T-Mobile NL) (Equal Weight) Q3 24: Positioned nicely for a possible IPO in 2025

SR trends continue to slide in aggregate, but Odido claimed that 2024 was always going to be a tough year for KPIs and SR (rebrand, T2 switch-off and commercial channel refurb), and talked confidently about the outlook for SR thanks to a mobile recovery (with a target of better postpaid adds going forward, so that it can take its “fair share of market growth”), and fixed gains.

EUR 9453.00

17h / 58m 17h / 58m 1 EN

Dominic Rose ... (+2)

Dominic Rose
Naresh Chouhan

EU Pharma 2025 Outlook - The Correction Was Due, Tread Carefully

In the aftermath of the H224 Healthcare correction, we look forward to 2025 with a more focused stock specific approach We show sector fundamentals have remained robust despite the correction. We see 4 key themes for the Pharma sector in 2025; 1) 2025 is a very strong year for important pipeline readouts, 2) The volume impact of Medicare Part D reform will dominate the narrative in H125 & continue to be a tailwind into 2026, 3) Margin expansion should be robust at a sector level, 4) Biotech M&A is likely to be materially higher than in 2024. As a result of these dynamics we change a number of...

EUR 4726.50

November 29, 2024 November 29, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Indus Towers (Neutral, pt INR 265, +18%) AMT sells Indian Towers - Implications for Indus Towers

Indus Towers (Reduce, INR 280 from INR 265, -26%) Implications for Indus of likely VIL nationalisation

Indus Towers (Reduce, TP: INR265, -40%) Proposed share buyback. Our thoughts.

Indian Mobile VIL Capital Increase – should you participate and what does it mean for Bharti, Jio and Indus? Indus to Reduce

TalkTalk H1 results: Guidance looks at risk

Odido (T-Mobile NL) (Equal Weight) Q3 24: Positioned nicely for a possible IPO in 2025

EU Pharma 2025 Outlook - The Correction Was Due, Tread Carefully

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe